Liminatus Pharma (LIMN) Competitors $1.60 +0.02 (+1.27%) As of 10/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock LIMN vs. MCRB, SLS, PLX, MIST, AVTX, TARA, CTOR, GNLX, NLTX, and ACTUShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include Seres Therapeutics (MCRB), SELLAS Life Sciences Group (SLS), Protalix BioTherapeutics (PLX), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Protara Therapeutics (TARA), Citius Oncology (CTOR), Genelux (GNLX), Neoleukin Therapeutics (NLTX), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors Seres Therapeutics SELLAS Life Sciences Group Protalix BioTherapeutics Milestone Pharmaceuticals Avalo Therapeutics Protara Therapeutics Citius Oncology Genelux Neoleukin Therapeutics Actuate Therapeutics Seres Therapeutics (NASDAQ:MCRB) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Does the media prefer MCRB or LIMN? In the previous week, Seres Therapeutics had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 2 mentions for Seres Therapeutics and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.38 beat Seres Therapeutics' score of 1.03 indicating that Liminatus Pharma is being referred to more favorably in the news media. Company Overall Sentiment Seres Therapeutics Positive Liminatus Pharma Positive Which has preferable valuation and earnings, MCRB or LIMN? Seres Therapeutics has higher revenue and earnings than Liminatus Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$126.32M1.36$140K-$4.60-4.27Liminatus PharmaN/AN/AN/AN/AN/A Is MCRB or LIMN more profitable? Liminatus Pharma's return on equity of 0.00% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A -350.16% -67.69% Liminatus Pharma N/A N/A N/A Do analysts prefer MCRB or LIMN? Seres Therapeutics presently has a consensus target price of $14.33, indicating a potential downside of 27.02%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals & insiders believe in MCRB or LIMN? 59.3% of Seres Therapeutics shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummarySeres Therapeutics beats Liminatus Pharma on 7 of the 10 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$41.10M$295.86M$2.52B$10.55BDividend YieldN/AN/A2.56%4.75%P/E RatioN/AN/A26.2527.60Price / SalesN/A325.37294.33224.03Price / CashN/AN/A47.1261.55Price / BookN/A3.3642.646.76Net IncomeN/A-$111.70M$6.99M$275.88M7 Day Performance-18.37%-7.35%0.98%2.81%1 Month Performance-34.69%1.09%3.12%9.24%1 Year PerformanceN/AN/A71.80%35.42% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$1.60+1.3%N/AN/A$41.10MN/A0.00N/APositive NewsEarnings ReportAnalyst ForecastMCRBSeres Therapeutics2.3191 of 5 stars$20.50+6.5%$14.33-30.1%+27.3%$179.38M$126.32M-4.46330Analyst ForecastSLSSELLAS Life Sciences Group2.2672 of 5 stars$1.69+5.0%$7.00+314.2%+58.2%$177.95MN/A-5.2810Positive NewsAnalyst ForecastShort Interest ↓PLXProtalix BioTherapeutics1.9628 of 5 stars$2.36+6.3%$15.00+535.6%+154.5%$177.01M$61.95M-18.15200Positive NewsMISTMilestone Pharmaceuticals2.3816 of 5 stars$2.05+2.5%$4.50+119.5%+30.7%$174.24MN/A-2.4430Positive NewsAnalyst ForecastAVTXAvalo Therapeutics3.1556 of 5 stars$12.96+2.0%$31.67+144.3%+47.7%$170.42M$440K0.0040High Trading VolumeTARAProtara Therapeutics1.9791 of 5 stars$4.41+1.4%$19.60+344.4%+191.4%$170.15MN/A-2.7230News CoveragePositive NewsAnalyst ForecastCTORCitius Oncology3.1288 of 5 stars$1.97-3.0%$6.00+204.6%+78.6%$169.53MN/A0.00N/ANews CoverageAnalyst ForecastGNLXGenelux1.435 of 5 stars$4.40+4.8%$20.33+362.1%+86.3%$166.19M$10K-5.1210Positive NewsAnalyst ForecastNLTXNeoleukin TherapeuticsN/A$17.33-2.1%N/A-53.4%$162.87MN/A-5.5790High Trading VolumeACTUActuate Therapeutics1.7607 of 5 stars$6.93+3.6%$20.33+193.4%+0.9%$161.07MN/A0.0010Analyst Forecast Related Companies and Tools Related Companies Seres Therapeutics Competitors SELLAS Life Sciences Group Competitors Protalix BioTherapeutics Competitors Milestone Pharmaceuticals Competitors Avalo Therapeutics Competitors Protara Therapeutics Competitors Citius Oncology Competitors Genelux Competitors Neoleukin Therapeutics Competitors Actuate Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
